ANNE LAM to Drug Resistance, Neoplasm
This is a "connection" page, showing publications ANNE LAM has written about Drug Resistance, Neoplasm.
Connection Strength
0.198
-
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leuk Lymphoma. 2019 01; 60(1):163-171.
Score: 0.102
-
Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. Eur J Haematol. 2017 Aug; 99(2):119-132.
Score: 0.096